These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9093552)

  • 1. Dynamic multidrug therapies for HIV: a control theoretic approach.
    Wein LM; Zenios SA; Nowak MA
    J Theor Biol; 1997 Mar; 185(1):15-29. PubMed ID: 9093552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.
    Wein LM; D'Amato RM; Perelson AS
    J Theor Biol; 1998 May; 192(1):81-98. PubMed ID: 9628841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2004 Sep; 66(5):1259-83. PubMed ID: 15294425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stochastic model for early HIV-1 population dynamics.
    Tuckwell HC; Le Corfec E
    J Theor Biol; 1998 Dec; 195(4):451-63. PubMed ID: 9837702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    Shi V; Tridane A; Kuang Y
    J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
    Fischl MA
    AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target cell limited and immune control models of HIV infection: a comparison.
    De Boer RJ; Perelson AS
    J Theor Biol; 1998 Feb; 190(3):201-14. PubMed ID: 9514649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modeling approach to the impact of HIV mutations on the immune system.
    Vergu E; Mallet A; Golmard JL
    Comput Biol Med; 2005 Jan; 35(1):1-24. PubMed ID: 15567349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance.
    Wodarz D
    J Theor Biol; 2001 Dec; 213(3):447-59. PubMed ID: 11735291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar HIV-1 evolution and immunological responses at 10 years despite several therapeutic strategies and host HLA Types.
    Arnedo-Valero M; Plana M; Mas A; Guilà M; Gil C; Castro P; Garcia F; Domingo E; Gatell JM; Pumarola T
    J Med Virol; 2004 Aug; 73(4):495-501. PubMed ID: 15221891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.